Makoto Mark Taketo, M.D., Ph.D.
Kitano Hospital in Osaka is operated by Tazuke Kofukai Medical Research Institute, and the Dean of Kyoto University Graduate School of Medicine has been appointed to the Chairman of the Board since its founding in 1928. As of 2019, the Director of the Research Institute was separated from the Hospital Director, and I was appointed as the first Institute Director. My mission is to pursue strong research programs at the Institute, helping physician scientists of Kitano Hospital in collaboration with Kyoto University. Please see below for research and education.
Research and EducationIn addition to my appointment as an Affiliate Professor of Graduate School of Medicine with Kitano Hospital Research Institute, I am also running a clinical research program “Personalized Therapeutics for Colon Cancer Patients” funded by iACT of Kyoto University Hospital.
We have established colon cancer stem cell spheroids from the primary tumors excised from ˜200 patients at Kyoto University Hospital. We have also demonstrated that the chemosensitivity of patients can be predicted by the response of stem cells in culture and/or xenografts. This approach allows prediction of clinical efficacy in a few months, without any burden to patients. Importantly, we can avoid prescribing inefficacious chemotherapeutics to the patients who will not respond to them (Figure 1).
We are clinically applying this method to not only chemotherapeutics that are already approved, but also to those under development. Namely, we reported recently that a subset of colorectal cancer patients may beneﬁt from FGFR inhibitor therapy (Figure 2).
For clinical development, we have established a venture company “Kyo Diagnostics, K.K.”
B. Eﬀects of various FGFR inhibitors on the in vitro growth of colorectal cancer spheroids.
- Sonoshita M, Aoki M, Fuwa H, Aoki K, Hosogi H, Sakai Y, Hashida H, Takabayashi A, Sasaki M, Robine S, Itoh K, Yoshioka K, Kakizaki F, Kitamura K, Oshima M, and Taketo M.M. (2011). Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 19: 125-137.
- Sonoshita M, Itatani Y, Kakizaki F, Sakimura K, Terashima T, Katsuyama U, Sakai Y, Taketo MM (2015). Promotion of Colorectal Cancer Invasion and Metastasis Through Activation of Notch–Dab1–Abl–RhoGEF Protein Trio. Cancer Discovery 5(2); 198-211.
- Miyoshi H, Maekawa H, Kakizaki F, Yamaura T, Kawada K, Sakai Y, and Taketo MM. (2018). An improved method for culturing patient-derived colorectal cancer spheroids. Oncotarget 9:21950-21964.
- Maekawa H, Miyoshi H, Yamaura T, Itatani Y, Kawada K, Sakai Y and Taketo MM. (2018). A chemosensitivity study of colorectal cancer using xenografts of patient-derived tumor initiating cells. Mol Cancer Therap. 17: 2187–2196.
- Yamamoto, T., Miyoshi, H., Kakizaki, F., Maekawa, H., Yamaura, T., Morimoto, T., Katayama, T., Kawada. K., Sakai, Y., Taketo, M. M. (2020). Chemosensitivity of patient-derived cancer stem cells identifies colorectal cancer patients with potential benefit from FGFR inhibitor therapy. Cancers (Basel) 12: E2010.
Personalized Therapeutics for Colon Cancer Patients iACT, Kyoto University HospitalMakoto Mark Taketo (Affiliate Professor)
Hiroyuki Miyoshi (Associate professor)
Fumihiko Kakizaki (Assistant professor）
Yuriko Fukui (Assistant administrative staff)
Office of Medical Research Institute, Kitano Hospital
Junko Ubuyashiki (Chief administrator)
Medical Research Institute, Kitano Hospital
Personalized Therapeutics for Colon Cancer Patients iACT, Kyoto University Hospital
Kyo Diagnostics K. K.